Anagram Therapeutics, Inc., a clinical stage company tackling complex gastrointestinal diseases, has raised $250.0M to advance its pipeline of enzyme-based therapies.
The company specializes in proprietary enzyme technologies aimed at solving malabsorption syndromes and nutrient metabolism disorders, which prevent the body from properly processing essential nutrients. Its lead product, ANG003, is a new class of broad-spectrum digestive enzyme replacement therapy intended for conditions like exocrine pancreatic insufficiency and malabsorption, offering a potential life-changing impact for patients with cystic fibrosis and other rare diseases.
